Insider Selling: Vertex Pharmaceuticals Incorporated (VRTX) CMO Sells $270,364.32 in Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) CMO Jeffrey Chodakewitz sold 1,719 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $157.28, for a total transaction of $270,364.32. Following the sale, the chief marketing officer now directly owns 56,143 shares of the company’s stock, valued at approximately $8,830,171.04. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Jeffrey Chodakewitz also recently made the following trade(s):

  • On Tuesday, January 2nd, Jeffrey Chodakewitz sold 3,438 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $151.80, for a total transaction of $521,888.40.
  • On Friday, November 3rd, Jeffrey Chodakewitz sold 5,390 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $144.71, for a total transaction of $779,986.90.
  • On Tuesday, October 31st, Jeffrey Chodakewitz sold 60,000 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $145.05, for a total transaction of $8,703,000.00.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $157.97 on Friday. The company has a market capitalization of $39,753.79, a P/E ratio of 202.53, a PEG ratio of 1.86 and a beta of 1.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.14 and a current ratio of 3.28. Vertex Pharmaceuticals Incorporated has a one year low of $80.06 and a one year high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.49. The company had revenue of $578.20 million during the quarter, compared to analysts’ expectations of $522.07 million. Vertex Pharmaceuticals had a return on equity of 9.23% and a net margin of 8.53%. The business’s revenue was up 39.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.16 EPS. sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 0.77 earnings per share for the current year.

VRTX has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $174.00 target price for the company in a research report on Tuesday, September 26th. BMO Capital Markets reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, September 27th. BTIG Research initiated coverage on shares of Vertex Pharmaceuticals in a research report on Friday, September 29th. They set a “buy” rating and a $200.00 target price for the company. DA Davidson initiated coverage on shares of Vertex Pharmaceuticals in a research report on Friday, September 29th. They set a “buy” rating and a $200.00 target price for the company. Finally, Royal Bank of Canada increased their target price on shares of Vertex Pharmaceuticals from $175.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, twenty-five have given a buy rating and one has given a strong buy rating to the stock. Vertex Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $175.89.

Several institutional investors have recently added to or reduced their stakes in VRTX. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Vertex Pharmaceuticals by 15.4% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock valued at $127,000 after buying an additional 132 shares during the last quarter. Smithfield Trust Co. purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at approximately $135,000. FNY Managed Accounts LLC purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at approximately $162,000. Fuller & Thaler Asset Management Inc. purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at approximately $198,000. Finally, Intact Investment Management Inc. purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at approximately $213,000. Institutional investors own 93.19% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Insider Selling: Vertex Pharmaceuticals Incorporated (VRTX) CMO Sells $270,364.32 in Stock” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://stocknewstimes.com/2018/01/20/insider-selling-vertex-pharmaceuticals-incorporated-vrtx-cmo-sells-270364-32-in-stock.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply